PL3307298T3 - Kompozycja wielopeptydowa - Google Patents

Kompozycja wielopeptydowa

Info

Publication number
PL3307298T3
PL3307298T3 PL16729347T PL16729347T PL3307298T3 PL 3307298 T3 PL3307298 T3 PL 3307298T3 PL 16729347 T PL16729347 T PL 16729347T PL 16729347 T PL16729347 T PL 16729347T PL 3307298 T3 PL3307298 T3 PL 3307298T3
Authority
PL
Poland
Prior art keywords
peptide composition
peptide
composition
Prior art date
Application number
PL16729347T
Other languages
English (en)
Inventor
Mark Peakman
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of PL3307298T3 publication Critical patent/PL3307298T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
PL16729347T 2015-06-10 2016-06-10 Kompozycja wielopeptydowa PL3307298T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1510056.3A GB201510056D0 (en) 2015-06-10 2015-06-10 Multi-peptide composition
EP16729347.1A EP3307298B1 (en) 2015-06-10 2016-06-10 Multi-peptide composition
PCT/GB2016/051726 WO2016198887A1 (en) 2015-06-10 2016-06-10 Multi-peptide composition

Publications (1)

Publication Number Publication Date
PL3307298T3 true PL3307298T3 (pl) 2020-06-29

Family

ID=53785229

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16729347T PL3307298T3 (pl) 2015-06-10 2016-06-10 Kompozycja wielopeptydowa

Country Status (26)

Country Link
US (1) US11400131B2 (pl)
EP (1) EP3307298B1 (pl)
JP (1) JP6969790B2 (pl)
KR (1) KR20180023948A (pl)
CN (1) CN107896494B (pl)
AR (1) AR104947A1 (pl)
AU (1) AU2016275295B2 (pl)
BR (1) BR112017026537A2 (pl)
CL (1) CL2017003143A1 (pl)
CO (1) CO2017012986A2 (pl)
EA (1) EA201890007A1 (pl)
EC (1) ECSP18001655A (pl)
ES (1) ES2778630T3 (pl)
GB (1) GB201510056D0 (pl)
HK (1) HK1253094A1 (pl)
IL (1) IL256199B2 (pl)
MA (1) MA41668A1 (pl)
MX (1) MX2017015658A (pl)
PE (1) PE20180450A1 (pl)
PH (1) PH12017501918A1 (pl)
PL (1) PL3307298T3 (pl)
TN (1) TN2017000517A1 (pl)
TW (1) TW201712027A (pl)
UY (1) UY36722A (pl)
WO (1) WO2016198887A1 (pl)
ZA (1) ZA201707873B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542488A (ja) * 1999-04-21 2002-12-10 ザイコス インク. 疾患を促進するcd4+tリンパ球によって認識されるペプチドエピトープ
US20030045467A1 (en) * 2001-01-05 2003-03-06 Tihamer Orban Autoantigen composition
GB0402129D0 (en) * 2004-01-30 2004-03-03 King S College London Therapeutic and diagnostic peptides
EP1709070B1 (en) * 2004-01-30 2013-05-29 King's College London Peptides for treatment of autoimmune diseases
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
WO2008083331A2 (en) * 2006-12-29 2008-07-10 The Regents Of The University Of Colorado Diagnostic and therapeutic target for autoimmune diseases and uses thereof
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. 循環バイオマーカー
CN104203263A (zh) * 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞

Also Published As

Publication number Publication date
WO2016198887A1 (en) 2016-12-15
HK1253094A1 (zh) 2019-06-06
AU2016275295B2 (en) 2021-12-09
EA201890007A1 (ru) 2018-05-31
EP3307298A1 (en) 2018-04-18
CA2984957A1 (en) 2016-12-15
AU2016275295A1 (en) 2017-12-07
JP6969790B2 (ja) 2021-11-24
CN107896494B (zh) 2021-09-03
ECSP18001655A (es) 2018-10-31
IL256199B2 (en) 2024-11-01
US11400131B2 (en) 2022-08-02
TN2017000517A1 (en) 2019-04-12
US20180221434A1 (en) 2018-08-09
CN107896494A (zh) 2018-04-10
JP2018524301A (ja) 2018-08-30
GB201510056D0 (en) 2015-07-22
PE20180450A1 (es) 2018-03-05
ES2778630T3 (es) 2020-08-11
PH12017501918A1 (en) 2018-03-19
IL256199A (en) 2018-02-28
UY36722A (es) 2017-01-31
AR104947A1 (es) 2017-08-23
IL256199B1 (en) 2024-07-01
KR20180023948A (ko) 2018-03-07
TW201712027A (zh) 2017-04-01
MX2017015658A (es) 2018-08-15
BR112017026537A2 (pt) 2019-11-12
CO2017012986A2 (es) 2018-03-09
CL2017003143A1 (es) 2018-05-18
EP3307298B1 (en) 2020-01-15
ZA201707873B (en) 2019-05-29
MA41668A1 (fr) 2018-03-30

Similar Documents

Publication Publication Date Title
GB201512030D0 (en) Composition
GB201506827D0 (en) Composition
GB201505527D0 (en) Composition
GB201521507D0 (en) Composition
GB201506830D0 (en) Composition
GB201506825D0 (en) Composition
GB201506829D0 (en) Composition
GB201515640D0 (en) Composition
GB201504665D0 (en) Composition
GB201616815D0 (en) Composition
GB201522681D0 (en) Composition
GB201522603D0 (en) Composition
GB201518348D0 (en) Composition
GB201515639D0 (en) Composition
GB201504307D0 (en) Composition
GB201519327D0 (en) Composition
GB201514585D0 (en) Composition
GB201506828D0 (en) Composition
GB201505520D0 (en) Composition
GB2537648B (en) Composition
GB201511697D0 (en) Composition
GB201509044D0 (en) Composition
GB201508722D0 (en) Composition
GB201521384D0 (en) Composition
GB201515734D0 (en) Composition